Canada: The Supreme Court On Screening Out Strikes Suits In Secondary Market Disclosure Class Actions: Theratechnologies Inc. V. 121851 Canada Inc.

Last Updated: April 22 2015
Article by David Di Paolo and James Gibson

Most Read Contributor in Canada, September 2016

On April 17, 2015, the Supreme Court released its decision in Theratechnologies Inc. v. 121851 Canada Inc., 2015 SCC 18: ( addressing two important issues in secondary market disclosure actions. First, how strong a case does the plaintiff have to show to obtain leave to proceed with the action? Second, do concerns or questions posed by a government body amount to a material change that requires timely disclosure?

The action arose when Theratechnologies Inc. (Thera), a pharmaceutical company and reporting issuer based in Montréal, filed a new drug application with the United States Food and Drug Administration (FDA) for a flagship drug to reduce abdominal fat in HIV patients. Thera had carried out a number of clinical trials to test the efficacy and the safety of the drug, including a potential increased risk of diabetes. The results of these clinical trials had been published, and Thera had publicly stated that there were "no major safety concerns" in respect of diabetes.

In the course of its review, the FDA provided Thera with a briefing document that included questions about the drug's potential side effects. When these questions were published, investors became concerned about whether the drug in fact posed an increased risk of diabetes. Thera's stock price dropped by 58 percent in the space of two days. Three days after the publication of these questions, however, the Advisory Committee of the FDA unanimously voted in favour of the drug, which was ultimately approved. Thera's stock price promptly recovered.

The plaintiff, a numbered company that had sold its Thera shares for a loss following the publication of the FDA's briefing document, sought leave to launch a class action against Thera. The plaintiff alleged that Thera had breached its obligation to make timely disclosure of a material change, being the concerns expressed by the FDA.

Under s. 225.4 of the Québec Securities Act, a court will only grant leave for such an action if the court "deems that the action is in good faith and there is a reasonable possibility that it will be resolved in favour of the plaintiff". In that regard, the language of this provision is similar to the language in s. 138.8 of the Ontario Securities Act. As noted by the Supreme Court, s. 225.4 was added as a screening mechanism to discourage frivolous "strike" suits against issuers.

The motions judge, Blanchard J., found that the action had a reasonable possibility of success and granted leave for the action to proceed (2012 QCCS 699, Gascon J.A. (as he then was), writing for the Québec Court of Appeal (2013 QCCA 1256, g10fx) found that the "reasonable possibility of success" standard was higher than the usual merits standard required to certify a class action. He found that this higher threshold had been met, and affirmed the decision of the motions judge.

The Supreme Court, however, unanimously allowed the appeal. Reviewing the origin and purpose of s. 225.4, Justice Abella agreed that the provision created a higher standard than the general threshold applicable to class actions. In her view, "a case with a reasonable possibility of success requires the claimant to offer both a plausible analysis of the applicable legislative provisions, and some credible evidence in support of the claim" (para. 39). This exercise requires the court to review the plaintiff's evidence, but not to engage in a "full analysis of the evidence", which would amount to a "mini-trial".

Applying this approach, Justice Abella noted that the clinical trials giving rise to the the FDA's questions had been disclosed to shareholders as they had become available, as had been the possibility of side effects. She concluded that the publication of the FDA's questions materials did not amount to a material change in Thera's operations, capital or business that required disclosure. Instead, it was an event that was external to the issuer and its business. As a result, the Court found that the plaintiff had failed to point to any evidence of a material change requiring disclosure, and accordingly had not established a reasonable possibility of success.

The Thera decision provides some welcome clarity as to how strong a plaintiff's case must be to proceed with a secondary market disclosure action. In Green v. Canadian Imperial Bank of Commerce, for example, the Ontario Court of Appeal had suggested that the applicable standard was similar to the threshold applicable to class actions, although with the benefit of an evidentiary record (at paras. 81-88). The reporting issuers appealed Green to the Supreme Court and asked for a more robust review of the plaintiff's case in a leave application; the appeal was heard on February 9, 2015 but remains under reserve.

The Thera decision appears to have provided at least some of the higher degree of scrutiny asked for by the Green appellants. Justice Abella suggests that the threshold applicable to leave applications ought to be higher than that applicable to the certification of class actions. The result is arguably a modestly tighter screening mechanism than was previously endorsed by the Court of Appeal, which may make it more difficult for plaintiffs to bring secondary market disclosure actions. The Supreme Court's decision in Green is likely to adopt the approach set out in Thera. However, reporting issuers will no doubt be interested in how the Court actually applies that approach to the facts in Green, which may provide more useful guidance to litigants beyond ensuring that they use the same language in describing the test applicable to leave motions.

With respect to material changes, the Thera decision may come as a welcome development for issuers, as the Court ultimately sided with the issuer in determining that no disclosure was required. Thera's previous disclosure of the results of the clinical trials no doubt assisted it when the FDA raised concerns about those potential side effects. The facts in this case, however, were sympathetic to the issuer, as the FDA ultimately approved its drug application, vindicating Thera's statements about the results of the clinical studies and restoring its share price. The concern noted by the Court of Appeal (at paras. 164-70, 146-150), that there might be a reasonable case that Thera had not sufficiently disclosed the substance of the FDA's concerns when stating the results of the studies, might carry greater weight if an issuer's published studies turn out to be less well-received than the studies were in this case.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.